US 12,234,290 B2
Nucleic acid-polypeptide compositions and uses thereof
Andrew John Geall, Carlsbad, CA (US); Venkata Ramana Doppalapudi, San Diego, CA (US); David Sai-Ho Chu, La Jolla, CA (US); Michael Caramian Cochran, La Jolla, CA (US); Rachel Elizabeth Johns, San Diego, CA (US); Palani Balu, Cupertino, CA (US); Rob Burke, Encinitas, CA (US); and Beatrice Diana Darimont, San Diego, CA (US)
Assigned to AVIDITY BIOSCIENCES, INC., San Diego, CA (US)
Filed by Avidity Biosciences, Inc., La Jolla, CA (US)
Filed on Feb. 26, 2021, as Appl. No. 17/187,669.
Application 17/187,669 is a continuation of application No. 15/476,849, filed on Mar. 31, 2017, abandoned.
Claims priority of provisional application 62/316,919, filed on Apr. 1, 2016.
Prior Publication US 2021/0179720 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/30 (2006.01); C12N 15/113 (2010.01); C12N 15/88 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 47/60 (2017.08); A61K 47/6807 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); A61K 48/0033 (2013.01); A61K 48/005 (2013.01); A61K 48/0075 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2851 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); C12N 15/1138 (2013.01); C12N 15/88 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/332 (2013.01); C12N 2310/3513 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01)] 23 Claims
 
1. A method of treating a disease or disorder in a patient in need thereof, comprising administering to said patient a composition comprising a molecule of Formula (I):
A-X1—B—X2—C  Formula I
wherein,
A is an antibody or antigen binding fragment thereof;
B consists of a double-stranded polynucleotide consisting of a passenger strand and a guide strand;
C is a polymer;
X1 is a bond or first non-polymeric linker; and
X2 is a bond or second non-polymeric linker;
wherein the double-stranded polynucleotide comprises at least one 2′ modified nucleotide, at least one modified internucleotide linkage, or at least one inverted abasic moiety; and
wherein A and C are attached in the same strand, but not attached to B at the same terminus.